[go: up one dir, main page]

BR9911220A - Métodos para ampliação dos nìveis de acetilcolina - Google Patents

Métodos para ampliação dos nìveis de acetilcolina

Info

Publication number
BR9911220A
BR9911220A BR9911220-5A BR9911220A BR9911220A BR 9911220 A BR9911220 A BR 9911220A BR 9911220 A BR9911220 A BR 9911220A BR 9911220 A BR9911220 A BR 9911220A
Authority
BR
Brazil
Prior art keywords
methods
acetylcholine levels
increasing acetylcholine
levels
acetylcholine
Prior art date
Application number
BR9911220-5A
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Michele Annette Glinn
Steven Marc Paul
Xin Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9911220A publication Critical patent/BR9911220A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção:<B>"MéTODOS PARA AMPLIAçãO DOS NìVEIS DE ACETILCOLINA"<D>. A presente invenção refere-se a um método para ampliação dos níveis de acetilcolina em mamíferos compreendendo a administração a um mamífero necessitando da mesma de uma quantidade eficaz de um composto da fórmula I e, opcionalmente, de um inibidor de AChE.
BR9911220-5A 1998-06-16 1999-06-04 Métodos para ampliação dos nìveis de acetilcolina BR9911220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8948998P 1998-06-16 1998-06-16
PCT/US1999/012525 WO1999065489A1 (en) 1998-06-16 1999-06-04 Methods for increasing levels of acetylcholine

Publications (1)

Publication Number Publication Date
BR9911220A true BR9911220A (pt) 2001-03-06

Family

ID=22217929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911220-5A BR9911220A (pt) 1998-06-16 1999-06-04 Métodos para ampliação dos nìveis de acetilcolina

Country Status (18)

Country Link
US (1) US6395719B1 (pt)
EP (1) EP0970695A1 (pt)
JP (1) JP2002518329A (pt)
KR (1) KR20010052891A (pt)
CN (1) CN1305377A (pt)
AU (1) AU751158B2 (pt)
BR (1) BR9911220A (pt)
CA (1) CA2335295A1 (pt)
EA (1) EA200100039A1 (pt)
HR (1) HRP20000862A2 (pt)
HU (1) HUP0102506A3 (pt)
IL (1) IL139015A0 (pt)
NO (1) NO20006087D0 (pt)
PL (1) PL344785A1 (pt)
SK (1) SK18792000A3 (pt)
TR (1) TR200003704T2 (pt)
WO (1) WO1999065489A1 (pt)
ZA (1) ZA200005887B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
GB0511003D0 (en) * 2005-05-28 2005-07-06 Univ Cardiff Screening and treatment of alzheimer's disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6489355B2 (en) 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5462950A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5534526A (en) 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
WO1995017095A1 (en) 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5552415A (en) 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5604248A (en) 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5512296A (en) 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
SG64896A1 (en) 1995-02-28 1999-05-25 Lilly Co Eli Benzothiophene compounds intermediates compositions and methods
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
IL120269A0 (en) 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
DK1019374T3 (da) 1996-06-07 2003-04-07 Eisai Co Ltd Polymorfe og Donepezil-hydrochlorid og fremstillingsfremgangsmåde
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
IL138914A0 (en) 1998-06-16 2001-11-25 Lilly Co Eli Methods for increasing levels of acetylcholine

Also Published As

Publication number Publication date
SK18792000A3 (sk) 2001-07-10
NO20006087L (no) 2000-11-30
NO20006087D0 (no) 2000-11-30
TR200003704T2 (tr) 2001-06-21
HUP0102506A3 (en) 2003-01-28
JP2002518329A (ja) 2002-06-25
CA2335295A1 (en) 1999-12-23
HUP0102506A2 (hu) 2002-01-28
EP0970695A1 (en) 2000-01-12
ZA200005887B (en) 2002-07-22
PL344785A1 (en) 2001-11-19
WO1999065489A1 (en) 1999-12-23
US6395719B1 (en) 2002-05-28
AU751158B2 (en) 2002-08-08
CN1305377A (zh) 2001-07-25
KR20010052891A (ko) 2001-06-25
EA200100039A1 (ru) 2001-06-25
AU4333899A (en) 2000-01-05
IL139015A0 (en) 2001-11-25
HRP20000862A2 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9814923A (pt) Método para tratamento de doença de alzheimer
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BR0113961A (pt) Método de analgesia
NO965568L (no) Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinaseinhibitorer
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR0109553A (pt) Método para o melhoramento de sinalização de ilhota em diabetes melito e para sua prevenção
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
NO20003018L (no) Triazinangiogenese-inhibitorer
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
EP1022026A3 (en) Pharmaceutical compositions for treating nitrate-induced tolerance
BR0211336A (pt) Métodos para o tratamento da fibrose do fìgado
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
PT1039894E (pt) Composicoes para o aumento da concentracao e/ou da mobilidade dos espermatozoides em humanos
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR9911220A (pt) Métodos para ampliação dos nìveis de acetilcolina
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
BR9911217A (pt) Métodos para ampliação dos nìveis de acetilcolina
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5,6,7 E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.